Incidence and Risk Factors of Bisphosphonate-Related Osteonecrosis of the Jaw in Multiple Myeloma Patients Having Undergone Autologous Stem Cell Transplantation
Authors:
- Natalie HöraufNHNatalie Hörauf
- Sven OttoSOSven Otto
- Christoph PautkeCPChristoph Pautke
- Emmo von TresckowETEmmo von Tresckow
- Tim RöhnischTRTim Röhnisch
- Philipp BaumannPBPhilipp Baumann
- Ralf SchmidmaierRSRalf Schmidmaier
- Irmgard BumederIBIrmgard Bumeder
- Fuat S. OduncuFOFuat S. Oduncu
- 1 January 2012
- journal article
- research article
- Published by S. Karger AG in Onkologie
- Vol. 35 (11) , 658-664
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a severe complication of bisphosphonate therapy. Due to their long survival and subsequently high cumulative doses of bisphosphonates, multiple myeloma patients have the highest risk of developing BRONJ of all patients treated with bisphosphonates. The purpose of the present study was to evaluate the incidence and risk factors for BRONJ in multiple myeloma patients after high-dose chemotherapy and autologous stem cell transplantation (ASCT). We retrospectively analyzed the data of 120 multiple myeloma patients after high-dose chemotherapy and ASCT treated with bisphosphonates and assessed the incidence and risk factors of BRONJ. Of the 120 patients, 23 (19%) developed BRONJ. 6 patients suffered several BRONJ events, resulting in a total incidence of 23%. The risk for BRONJ was significantly higher for patients with rheumatism and recent dental manipulations. Furthermore, the number of previous bisphosphonate rotations, the duration of bisphosphonate therapy, and the type and cumulative dose of bisphosphonate used were associated with the incidence of BRONJ. Our study is the first to determine the risk of BRONJ in a homogeneous group of multiple myeloma patients treated with high-dose chemotherapy and ASCT.Keywords
This publication has 40 references indexed in Scilit:
- A Role of Oral Bacteria in Bisphosphonate-induced Osteonecrosis of the JawJournal of Dental Research, 2011
- Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trialThe Lancet Oncology, 2011
- Use of Bisphosphonates and Reduced Risk of Colorectal CancerJournal of Clinical Oncology, 2011
- First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trialThe Lancet, 2010
- Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal WomenJournal of Clinical Oncology, 2010
- Prevalence of bisphosphonate associated osteonecrosis of the jaws in multiple myeloma patientsHead & Face Medicine, 2010
- Influence of bisphosphonates on endothelial cells, fibroblasts, and osteogenic cellsClinical Oral Investigations, 2009
- Inhibition of Oral Mucosal Cell Wound Healing by BisphosphonatesJournal of Oral and Maxillofacial Surgery, 2008
- A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patientsAnnals of Oncology, 2007
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005